A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

  1. Martín, M.
  2. Chan, A.
  3. Dirix, L.
  4. O'Shaughnessy, J.
  5. Hegg, R.
  6. Manikhas, A.
  7. Shtivelband, M.
  8. Krivorotko, P.
  9. Batista López, N.
  10. Campone, M.
  11. Ruiz Borrego, M.
  12. Khan, Q.J.
  13. Beck, J.T.
  14. Ramos Vázquez, M.
  15. Urban, P.
  16. Goteti, S.
  17. Di Tomaso, E.
  18. Massacesi, C.
  19. Delaloge, S.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2017

Alea: 28

Zenbakia: 2

Orrialdeak: 313-320

Mota: Artikulua

DOI: 10.1093/ANNONC/MDW562 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus